Pricing
What is the lowest-cost way to get Wegovy or Zepbound in 2026?
Compare confirmed insurance copays, manufacturer cash offers and required care fees without confusing a starting price with the cheapest complete option.
Claims are checked against the sources cited in this article. Nothing here is individualized medical advice. How we research
On this page
As checked October 9, 2026, the lowest advertised medication-payment routes include commercial coverage with an eligible savings card for as little as $25, or the Medicare GLP-1 Bridge at $50 per monthly fill for eligible Part D beneficiaries. Without those routes, manufacturer cash offers start at $149 for Wegovy tablets, $199 for each of two eligible introductory Wegovy pen fills, or $299 for a Zepbound vial/KwikPen supply—plus required needles or syringes and any separately billed care fees. These are conditional product-specific offers, not a guaranteed lowest total for everyone. Sources: NovoCare, LillyDirect, and CMS Bridge rules.
The lowest-payment routes have different eligibility rules
Commercial savings cards require the applicable private-insurance coverage and offer qualifications. Novo’s covered offer advertises as little as $25, with savings capped at $100 per month; that cap means a larger insured bill is not automatically reduced to $25. Government beneficiaries are excluded from those cards. Lilly’s covered single-dose Zepbound pen savings program has its own limits and is separate from vial/KwikPen cash pricing.
For eligible Medicare Part D beneficiaries, the temporary Bridge charges $50 for a monthly fill of Wegovy injection or tablets, or Zepbound KwikPen—not Zepbound vials or single-dose pens. It runs July 1, 2026 through December 31, 2027. The $50 is a medication copay, not a provider membership or consultation quote. Medicare’s product list explains the program; actual eligibility must be confirmed, not inferred from Medicare enrollment alone.
If you do not qualify for an insured or Bridge route, compare the manufacturer cash offer for the actual prescription. LillyDirect requires pen needles for KwikPen or needles and syringes for vials but does not list their prices on the product page. Do not treat those unquoted required purchases as free. Confirm the complete bill before deciding which payment route is least expensive for you.
Compare payment channels, not just advertisements
The first distinction is between an insurance transaction and a cash transaction. A low commercial-insurance headline is not necessarily available without coverage, and a cash offer is not necessarily the best financial route for someone whose plan pays for the actual prescription. Ask the pharmacy to label each quote before deciding which is less expensive.
The second distinction is between the medicine and the care service. A telehealth membership can provide clinician access while the pharmacy collects payment separately. An in-person clinician can also issue a prescription, with the visit billed under its own terms. The cheapest pharmacy offer does not by itself establish the cheapest overall route to care.
Use the exact prescription as your starting point. Product form and package matter: a tablet bottle, a box of pens and a vial supply are not interchangeable billing labels. This article compares purchasing channels, not medical suitability or the clinical differences between treatments.
Route 1: a confirmed insurance quote
If you have prescription coverage, ask the insurer or pharmacy what you would pay for the named product under the current plan. Request the exact form and package, any authorization requirement, and the patient charge for the proposed fill. A general statement that a plan “covers GLP-1s” does not answer those transaction-specific questions.
Where applicable, ask whether a manufacturer commercial savings offer can be applied to the remaining charge. Novo’s Wegovy offer advertises a possible $25 payment but caps savings at $100 per month and excludes government beneficiaries. Its current footnotes explain the limits. Do not assume that the headline guarantees a $25 bill after every plan calculation.
Compare a confirmed insured quote, not a guessed copay, with the cash alternative. Keep the deductible and out-of-pocket implications visible as separate facts. Novo explicitly says purchases outside insurance do not accumulate toward those insurance limits. A smaller cash transaction today can therefore be different from a smaller total insurance-related expense over a longer period.
Route 2: manufacturer self-pay offers
Manufacturer channels provide a public reference when insurance does not cover the prescription or you are considering paying outside it. The important details are the product, current price, eligibility, supply quantity and future price.
For Wegovy pens, the eligible $199 offer covers two introductory fills of 0.25 or 0.5 mg through December 31, 2026; standard offers are $349 for the listed non-HD strengths or $399 for HD. Wegovy tablets range from $149 to $299 by strength. These are Novo’s product-specific offers, not a prescribed progression.
For Zepbound, the $449 Journey price at 7.5–15 mg applies to the first qualifying purchase, with later refill purchases required within 45 days of the prior delivery or receipt. Without the offer, regular higher-strength prices are $499 or $699. The 28-day package is four vials or one KwikPen. Lilly’s purchase terms distinguish that offer from single-dose pen programs.
Record both the qualifying price and fallback amount. A program can be affordable while an introductory or purchasing condition applies, yet less affordable once it does not. Do not alter a prescription to chase a price; ask the pharmacy and care team for the relevant quote.
Route 3: separate care from pharmacy purchasing
Before joining a program, ask whether you can use the applicable manufacturer pharmacy offer with a prescription from your existing clinician. The answer depends on the prescription and pharmacy process; it should not be assumed from an advertisement.
If you need a new care service, compare its required charges independently. Our weight-care directory and company profiles describe services and payment structures. Their existence does not guarantee that a provider offers every medicine, accepts your insurance or provides a prescription.
A service comparison should identify the initial visit, any ongoing membership and what those payments include. Ask whether enrollment is charged before the prescription decision and what happens if no prescription is issued. This avoids comparing one platform’s medicine-only price with another platform’s bundled medicine-and-care price.
A worksheet for the lowest complete cost
Create one row per actual offer and keep these columns:
| Item | What to record |
|---|---|
| Product | Brand, form, strength, quantity and days supplied |
| Payment route | Insurance or specific cash offer |
| First payment | All mandatory cash due to begin |
| Comparison period | Purchases required for the chosen interval |
| Ongoing payment | Price after introductory discounts |
| Conditions | Eligibility, offer deadline and refill rule |
| Commitment | Prepayment, renewal and cancellation terms |
| Unresolved costs | Fees not confirmed in the quote |
Twelve weeks is 84 days. Three 28-day supplies cover that interval, while three 30-day supplies cover 90 days. Keep that difference visible. A monthly equivalent on a prepaid plan also does not show the full cash amount needed at checkout.
Do not rank an incomplete quote as cheapest merely because unconfirmed charges were entered as zero. Equally, do not invent a fee to make a complete offer look worse. Use known amounts, state assumptions and retain unknowns.
Cheap compounded offers are a different category
An advertisement for compounded semaglutide or tirzepatide is not a branded Wegovy or Zepbound quote. FDA explains that compounded drugs are not FDA-approved and do not undergo its premarket review. FDA’s compounding questions and answers supply that regulatory distinction.
Our compounded GLP-1 price overview keeps those offers separate and shows commitments and required payments. It does not establish substitution or clinical equivalence. The most useful “cheapest” answer is the lowest complete confirmed quote for the actual prescription and payment route, not the lowest isolated number on the internet.
For context, the October 6 reviewed monthly injection examples include Gentle Health starting at $135 for semaglutide, and a $169 tirzepatide example from both Gentle and Mochi Health. These are different prescribed tiers, not equal-dose trials or branded-drug offers. Gentle’s terms require two monthly payments, while Mochi’s representative amount includes membership and leaves account-specific pricing and its FAQ/terms fee discrepancy to confirm. Compare those records alongside OrderlyMeds, Henry Meds or DirectCare AI where the relevant product is actually listed; do not replace a branded price with a compounded headline.